Response of patients with indolent systemic mastocytosis to tamoxifen citrate

Joseph H. Butterfield, Dong Chen

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

We examined whether tamoxifen citrate at 20mg/day for 1 year had a beneficial effect on laboratory findings, bone marrow mastocytosis, common clinical symptoms, or quality-of-life assessment for 5 women and 2 men with indolent systemic mastocytosis. Tamoxifen was well tolerated. We found significant reductions in the platelet count, serum alkaline phosphatase, and 24-h urinary excretion of N-methylhistamine and significant increases in serum lactate dehydrogenase and (excluding 2 patients taking aspirin) in 24-h urinary excretion of 11β-prostaglandin F. Overall, no change occurred in percent involvement of bone marrow by mastocytosis. Symptom scores were mild and did not change during the treatment. The 36-Item Short Form Health Survey scores for quality of life physical and mental components showed no marked changes. Tamoxifen, an older, nonhematotoxic medication, has limited activity in systemic mastocytosis at the dosage used in this study.

Original languageEnglish (US)
JournalLeukemia Research
DOIs
StateAccepted/In press - Aug 26 2015

Fingerprint

Systemic Mastocytosis
Tamoxifen
Mastocytosis
Bone Marrow
Quality of Life
Dinoprost
Health Surveys
Serum
Platelet Count
Aspirin
Alkaline Phosphatase
Therapeutics

Keywords

  • 11β-prostaglandin F
  • N-Methylhistamine
  • Systemic mastocytosis
  • Tamoxifen
  • Tryptase

ASJC Scopus subject areas

  • Cancer Research
  • Hematology
  • Oncology

Cite this

Response of patients with indolent systemic mastocytosis to tamoxifen citrate. / Butterfield, Joseph H.; Chen, Dong.

In: Leukemia Research, 26.08.2015.

Research output: Contribution to journalArticle

@article{5422713af5d54a619457294101f40f81,
title = "Response of patients with indolent systemic mastocytosis to tamoxifen citrate",
abstract = "We examined whether tamoxifen citrate at 20mg/day for 1 year had a beneficial effect on laboratory findings, bone marrow mastocytosis, common clinical symptoms, or quality-of-life assessment for 5 women and 2 men with indolent systemic mastocytosis. Tamoxifen was well tolerated. We found significant reductions in the platelet count, serum alkaline phosphatase, and 24-h urinary excretion of N-methylhistamine and significant increases in serum lactate dehydrogenase and (excluding 2 patients taking aspirin) in 24-h urinary excretion of 11β-prostaglandin F2α. Overall, no change occurred in percent involvement of bone marrow by mastocytosis. Symptom scores were mild and did not change during the treatment. The 36-Item Short Form Health Survey scores for quality of life physical and mental components showed no marked changes. Tamoxifen, an older, nonhematotoxic medication, has limited activity in systemic mastocytosis at the dosage used in this study.",
keywords = "11β-prostaglandin F, N-Methylhistamine, Systemic mastocytosis, Tamoxifen, Tryptase",
author = "Butterfield, {Joseph H.} and Dong Chen",
year = "2015",
month = "8",
day = "26",
doi = "10.1016/j.leukres.2015.11.004",
language = "English (US)",
journal = "Leukemia Research",
issn = "0145-2126",
publisher = "Elsevier Limited",

}

TY - JOUR

T1 - Response of patients with indolent systemic mastocytosis to tamoxifen citrate

AU - Butterfield, Joseph H.

AU - Chen, Dong

PY - 2015/8/26

Y1 - 2015/8/26

N2 - We examined whether tamoxifen citrate at 20mg/day for 1 year had a beneficial effect on laboratory findings, bone marrow mastocytosis, common clinical symptoms, or quality-of-life assessment for 5 women and 2 men with indolent systemic mastocytosis. Tamoxifen was well tolerated. We found significant reductions in the platelet count, serum alkaline phosphatase, and 24-h urinary excretion of N-methylhistamine and significant increases in serum lactate dehydrogenase and (excluding 2 patients taking aspirin) in 24-h urinary excretion of 11β-prostaglandin F2α. Overall, no change occurred in percent involvement of bone marrow by mastocytosis. Symptom scores were mild and did not change during the treatment. The 36-Item Short Form Health Survey scores for quality of life physical and mental components showed no marked changes. Tamoxifen, an older, nonhematotoxic medication, has limited activity in systemic mastocytosis at the dosage used in this study.

AB - We examined whether tamoxifen citrate at 20mg/day for 1 year had a beneficial effect on laboratory findings, bone marrow mastocytosis, common clinical symptoms, or quality-of-life assessment for 5 women and 2 men with indolent systemic mastocytosis. Tamoxifen was well tolerated. We found significant reductions in the platelet count, serum alkaline phosphatase, and 24-h urinary excretion of N-methylhistamine and significant increases in serum lactate dehydrogenase and (excluding 2 patients taking aspirin) in 24-h urinary excretion of 11β-prostaglandin F2α. Overall, no change occurred in percent involvement of bone marrow by mastocytosis. Symptom scores were mild and did not change during the treatment. The 36-Item Short Form Health Survey scores for quality of life physical and mental components showed no marked changes. Tamoxifen, an older, nonhematotoxic medication, has limited activity in systemic mastocytosis at the dosage used in this study.

KW - 11β-prostaglandin F

KW - N-Methylhistamine

KW - Systemic mastocytosis

KW - Tamoxifen

KW - Tryptase

UR - http://www.scopus.com/inward/record.url?scp=84947600497&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84947600497&partnerID=8YFLogxK

U2 - 10.1016/j.leukres.2015.11.004

DO - 10.1016/j.leukres.2015.11.004

M3 - Article

JO - Leukemia Research

JF - Leukemia Research

SN - 0145-2126

ER -